{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-076304","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.353103+00:00","generated_at":"2026-05-20T18:24:19.480613+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Dianthus director Moulder resigns; Read appointed as Class III director","bullets":["Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.","Board appointed Simon Read, Ph.D. as Class III director and to S&T and N&CG Committees.","Dr. Read receives initial option for 25,000 shares vesting over 3 years; cash compensation of $40k/yr plus $5k per committee.","Annual meeting elected Garcia and Soteropoulos as Class I directors; advisory vote approved exec compensation; Deloitte ratified as auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-076304","json":"https://secwatch.observer/filing/0000950170-25-076304.json","markdown":"https://secwatch.observer/filing/0000950170-25-076304.md","text":"https://secwatch.observer/filing/0000950170-25-076304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/0000950170-25-076304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/dnth-20250522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T18:24:19.480613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"513af6b061","claim":"Simon Read was appointed as Class III director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/0000950170-25-076304-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"a4685e22a3","claim":"Leon O. Moulder, Jr. resigned as Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/0000950170-25-076304-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}